Baxter International Inc. (NYSE:BAX) today announced that it has entered
into a manufacturing services agreement with Stichting Sanquin
Bloedvoorziening (Sanquin Blood Supply Foundation) in the Netherlands
that will provide Baxter up to 1.6 million liters of incremental plasma
fractionation capacity annually to support global growth of
plasma-derived treatments.
Under the agreement, Baxter will pay Sanquin a fixed fee to fractionate
plasma used for medications to treat immune disorders, hemophilia,
trauma and other critical conditions. Sanquin will process plasma
supplied by Baxter into bulk material for GAMMAGARD LIQUID 10% [Immune
Globulin Infusion (Human)], (marketed as KIOVIG outside the United
States and Canada), and FLEXBUMIN [Albumin (Human)]. Sanquin also will
provide filling and finishing for IMMUNATE. The initial term of the
agreement is 10 years, with production beginning in 2014 and Sanquin
reaching the full 1.6 million liters annually by the end of 2016.
''As a worldwide leader in plasma-derived therapies, Baxter is committed
to efforts that support the availability of our treatments for the
patients who need them. Our collaboration with Sanquin is an important
step in addressing both the near and long-term needs of the patient
community,'' said Ludwig Hantson, Ph.D., president of Baxter's
BioScience business.
Earlier this year, Baxter announced plans to build a new
state-of-the-art manufacturing facility in Georgia to support future
growth of its plasma-based treatments. Construction will begin this year
at the site near Covington, Ga. Commercial production is scheduled to
begin in 2018, with the new plasma fractionation facility adding up to
3.0 million liters of new capacity annually when fully operational, with
the flexibility and necessary infrastructure to expand further to
support additional global market needs.